Key facts
- Warburg Pincus is reportedly nearing a deal to acquire PANTHERx Rare for more than $7 billion.
- Abu Dhabi Investment Authority is partnering with Warburg Pincus on the potential acquisition.
- PANTHERx Rare specializes in medicines and patient support for rare and orphan diseases.
- The company is currently owned by an investor group including General Atlantic.
- The potential deal comes as private equity firms look to increase deal activity.
Private equity firm Warburg Pincus is reportedly close to acquiring specialty pharmacy company PANTHERx Rare for more than $7 billion, including debt. The Wall Street Journal reported the potential deal, citing sources familiar with the matter. Warburg Pincus is partnering with Abu Dhabi Investment Authority on the acquisition, and a deal could be finalized soon, though sources cautioned that it is not yet finalized and the timing could still slip.
Pittsburgh-based PANTHERx specializes in providing medicines and patient support services for rare and orphan diseases. The company is currently owned by an investor group that includes private equity firm General Atlantic, Nautic Partners, and The Vistria Group. Centene had previously sold PANTHERx in 2022 to this consortium as the insurer streamlined its business.
The potential acquisition occurs at a time when private equity firms are seeking to increase deal activity due to a backlog of portfolio companies awaiting exits. Warburg Pincus, which manages over $100 billion in assets, has a history of healthcare investments.